Linda Volkers

Linda Volkers

Auto-generated profile, based on publicly available information

Linda Volkers

Department of Cardiology, Heart Lung Center Leiden, Leiden University Medical Center, 2333 ZA Leiden, Netherlands

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
JBJacqueline M. Bliley
Jacqueline M. Bliley
MVMathilde Vermeer
Mathilde Vermeer
RDRebecca M. Duffy
Rebecca M. Duffy
IBIvan Batalov
Ivan Batalov
DKDuco Kramer
Duco Kramer
AFAdam Walter Feinberg
Adam Walter Feinberg
A dynamic mechanical loading platform was developed to improve contractility of engineered heart tissues and study cardiac disease progression.

27 February 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
ENEmile C. A. Nyns
Emile C. A. Nyns
RPRené Poelma
René Poelma
LVLinda Volkers
Linda Volkers
JPJaap J. Plomp
Jaap J. Plomp
CBCindy I. Bart
Cindy I. Bart
DPDaniël A. Pijnappels
Daniël A. Pijnappels
An implanted light source coupled with local gene therapy generates an automated shock-free system to treat atrial fibrillation in rats.

18 June 2018 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
JLJia Liu
Jia Liu
LVLinda Volkers
Linda Volkers
WJWanchana Jangsangthong
Wanchana Jangsangthong
CBCindy I Bart
Cindy I Bart
MEMarc C Engels
Marc C Engels
AVAntoine de Vries
Antoine de Vries
The generation of homogeneous cardiomyocyte populations from fresh tissue or stem cells is laborious and costly. A potential solution to this problem would be to establish lines of immortalized cardiomyocytes. However, as proliferation and (terminal) differentiation of cardiomyocytes are mutually exclusive processes, their permanent immortalization causes loss of electrical and mechanical functions. We therefore aimed at developing conditionally immortalized atrial myocyte (iAM) lines allowing toggling between proliferative and contractile phenotypes by a single-component change in culture medium composition. Freshly isolated neonatal rat atrial cardiomyocytes (AMs) were transduced with a lentiviral vector conferring doxycycline (dox)-controlled expression of simian virus 40 large T antigen. Under proliferative conditions (i.e. in the presence of dox), the resulting cells lost most cardiomyocyte traits and doubled every 38 h. Under differentiation conditions (i.e. in the absence of dox), the cells stopped dividing and spontaneously reacquired a phenotype very similar to that of primary AMs (pAMs) in gene expression profile, sarcomeric organization, contractile behaviour, electrical properties, and response to ion channel-modulating compounds (as assessed by patch-clamp and optical voltage mapping). Moreover, differentiated iAMs had much narrower action potentials and propagated them at >10-fold higher speeds than the widely used murine atrial HL-1 cells. High-frequency electrical stimulation of confluent monolayers of differentiated iAMs resulted in re-entrant conduction resembling atrial fibrillation, which could be prevented by tertiapin treatment, just like in monolayers of pAMs. Through controlled expansion and differentiation of AMs, large numbers of functional cardiomyocytes were generated with properties superior to the differentiated progeny of existing cardiomyocyte lines. iAMs provide an attractive new model system for studying cardiomyocyte proliferation, differentiation, metabolism, and (electro)physiology as well as to investigate cardiac diseases and drug responses, without using animals.

18 June 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
WWWout Weuring
Wout Weuring
SSSakshi Singh
Sakshi Singh
LVLinda Volkers
Linda Volkers
MRMartin B Rook
Martin B Rook
RSRuben H. van ‘T Slot
Ruben H. van ‘T Slot
BKBobby P.C. Koeleman
Bobby P.C. Koeleman
Dravet syndrome is caused by dominant loss-of-function mutations in SCN1A which cause reduced activity of Nav1.1 leading to lack of neuronal inhibition. On the other hand, gain-of-function mutations in SCN8A can lead to a severe epileptic encephalopathy subtype by over activating Na V 1.6 channels. These observations suggest that Nav1.1 and Nav1.6 represent two opposing sides of the neuronal balance between inhibition and activation. Here, we hypothesize that Dravet syndrome may be treated by either enhancing Nav1.1 or reducing Nav1.6 activity. To test this hypothesis we generated and characterized a novel DS zebrafish model and tested new compounds that selectively activate or inhibit the human Na V 1.1 or Na V 1.6 channel respectively. We used CRISPR/Cas9 to generate two separate Scn1Lab knockout lines as an alternative to previous knock-down models. Using an optimized locomotor assay, spontaneous burst movements were detected that were unique to Scn1Lab knockouts and disappear when introducing human SCN1A mRNA. Besides the behavioral phenotype, Scn1Lab knockouts show sudden, electrical discharges in the brain that indicate epileptic seizures in zebrafish. Scn1Lab knockouts showed increased sensitivity to the convulsant pentylenetetrazole and a reduction in whole organism GABA levels. Drug screenings further validated a Dravet syndrome phenotype. We tested the Na V 1.1 activator AA43279 and our newly synthesized Na V 1.6 inhibitors MV1369 and MV1312 in the Scn1Lab knockouts. Both type of compounds significantly reduced the number of burst movements. Our results show that selective inhibition of Na V 1.6 could be just as efficient as selective activation of Na V 1.1 and these approaches could prove to be novel potential treatment strategies for Dravet syndrome and other (genetic) epilepsies. Compounds tested in zebrafish however, should always be further validated in other model systems, preferably human derived.

27 May 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
JBJacqueline M. Bliley
Jacqueline M. Bliley
MVMathilde Vermeer
Mathilde Vermeer
RDRebecca M. Duffy
Rebecca M. Duffy
IBIvan Batalov
Ivan Batalov
DKDuco Kramer
Duco Kramer
AFAdam Walter Feinberg
Adam Walter Feinberg
The role mechanical forces play in shaping the structure and function of the heart is critical to understanding heart formation and the etiology of disease but is challenging to study in patients. Engineered heart tissues (EHTs) incorporating human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes have the potential to provide insight into these adaptive and maladaptive changes in the heart. However, most EHT systems are unable to model both preload (stretch during chamber filling) and afterload (pressure the heart must work against to eject blood). Here, we have developed a new dynamic EHT (dyn-EHT) model that enables us to tune preload and have unconstrained fractional shortening of >10%. To do this, 3D EHTs are integrated with an elastic polydimethylsiloxane (PDMS) strip that provides mechanical pre- and afterload to the tissue in addition to enabling contractile force measurements based on strip bending. Our results demonstrate in wild-type EHTs that dynamic loading is beneficial based on the magnitude of the forces, leading to improved alignment, conduction velocity, and contractility. For disease modeling, we use hiPSC–derived cardiomyocytes from a patient with arrhythmogenic cardiomyopathy (ACM) due to mutations in desmoplakin. We demonstrate that manifestation of this desmosome-linked disease state requires the dyn-EHT conditioning and that it cannot be induced using 2D or standard 3D EHT approaches. Thus, dynamic loading strategy is necessary to provoke a disease phenotype (diastolic lengthening, reduction of desmosome counts, and reduced contractility), which are akin to primary endpoints of clinical disease, such as chamber thinning and reduced cardiac output. Single Sentence Summary: Development of a dynamic mechanical loading platform to improve contractile function of engineered heart tissues and study cardiac disease progression.